Risk-Adapted High Dose Chemoradiotherapy and Autologous Stem Cell Transplantation for Patients With Relapsed and Primary Refractory Hodgkin's Lymphoma
- Determine whether event-free survival of patients with low to high-intermediate risk,
relapsed or refractory Hodgkin's lymphoma can be improved when treated with
cytoreductive combination chemotherapy followed by radiotherapy, high-dose combination
chemotherapy, and autologous stem cell transplantation.
- Determine the toxic effects of this regimen in these patients.
OUTLINE: Patients are stratified according to risk factors (low or low-intermediate risk
[0-1 risk factor] vs high-intermediate risk [2 risk factors]).
- ICE-based cytoreductive chemotherapy: Patients are assigned to 1 of 2 treatment groups.
- Group I (patients with low or low-intermediate risk disease): Patients receive ICE
comprising ifosfamide IV and carboplatin IV once on day 2 and etoposide IV over 1
hour once daily on days 1-3. Patients then receive ifosfamide IV twice on day 15,
carboplatin IV once on day 17 and etoposide IV over 1 hour twice daily on days
- Group II (patients with high-intermediate risk disease): Patients receive
ifosfamide IV twice on days 1 and 17, carboplatin IV once on days 3 and 19, and
etoposide IV over 1 hour twice daily on days 1-3 and 17-19.
In both groups, patients undergo stem cell collection after either the first or second OR
first and second courses of ICE.
- Stem cell mobilization and collection: Patients receive filgrastim (G-CSF)
subcutaneously (SC) beginning on day 5 and continuing until stem cell collection is
completed. Patients undergo a maximum of 5 daily apheresis sessions. Patients who
mobilize fewer than the required minimal number of stem cells repeat apheresis with
high-dose G-CSF alone or undergo bone marrow harvest. Patients then proceed to
radiotherapy, high-dose chemotherapy (HDC), and autologous stem cell transplant (ASCT)
OR noncross-resistant chemotherapy based on response to ICE-based cytoreductive
- Restaging studies: Patients undergo restaging studies with CT scan and positron
emission tomography (PET). Patients who are chemosensitive with a normal PET scan
proceed to radiotherapy, HDC, and ASCT. Patients who progress on ICE, or who respond
but have an abnormal PET scan, proceed to noncross-resistant chemotherapy comprising
gemcitabine hydrochloride, vinorelbine, and doxorubicin HCl liposome (GND).
- GND chemotherapy: Patients receive gemcitabine hydrochloride IV, vinorelbine IV, and
doxorubicin HCl liposome IV on days 1, 15, 29, and 43. Patients then proceed to
radiotherapy, HDC, and ASCT in the absence of disease progression.
- Radiotherapy: Within 2 weeks after completion of the ICE or GND regimen, patients who
have no history of prior radiotherapy receive radiotherapy according to stratification
by disease extent (isolated lymph nodes vs ≥ 2 contiguous nodal-based masses with or
without extensive small-volume lymphadenopathy vs extensive small-volume
lymphadenopathy). These patients undergo either involved-field radiotherapy (IFRT)
twice daily over 1-2 weeks, total lymphoid irradiation (TLI) twice daily over 1 week,
or both concurrently.
- HDCT: Patients who undergo TLI only OR IFRT and TLI receive high-dose cyclophosphamide
IV twice daily and etoposide IV once daily on days -5 and -2. Patients who undergo IFRT
only OR do not undergo radiotherapy receive high-dose cyclophosphamide IV twice daily
and etoposide IV once daily on days -6 and -3 and carmustine IV once on day -2.
- ASCT: Patients undergo ASCT or reinfusion of bone marrow, if harvested, on day -1 or 0.
Patients then receive G-CSF beginning on day 5 and continuing until blood counts
After completion of study treatment, patients are followed periodically for 15 months.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Event-free survival at 3 years
Craig Moskowitz, MD
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|